About Mavacamten

Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy.  Echo-based titration will be required and the HCMA recommends evaluation by a recognized Center of Excellence in shared decision making regarding health care choices

Camzyos is only available through a restricted program called the Camzyos REMS Program because of the risk of heart failure due to systolic dysfunction. Notable requirements of the Camzyos REMS Program include the following:

Prescribers must be certified by enrolling in the REMS Program.

Patients must enroll in the REMS Program and comply with ongoing monitoring requirements.

Pharmacies must be certified by enrolling in the Camzyos REMS Program and must only dispense to patients who are authorized to receive Camzyos.

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is pleased to announce that it has opened a new fund to assist individuals living with cardiomyopathy. Through the new fund, HealthWell will provide up to $10,000 in medication copayment or insurance premium assistance for a 12-month grant period to eligible Medicare patients who have annual household incomes up to 500 percent of the federal poverty level.

“For many living with cardiomyopathy, the ability to carry out normal daily functions can be compromised due to symptoms such as shortness of breath, swelling of the feet and legs, and fatigue,” said HealthWell Foundation President, Krista Zodet. “These symptoms, among others, can cause the patient undue stress, which can further exacerbate their condition. For cardiomyopathy patients who are on Medicare, the financial burden alone can attribute to stress and fatigue. We are honored that our donors understand these challenges and have provided HealthWell with the financial resources to assist Medicare patients who would otherwise forgo proper treatment of their condition due to cost.”